Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Click here to select your areas of interest

Areas of interest

Select to filter on program types

E-learnings, Meet the author 06/07/2020

Meet the Author: prof. Brian Rini and prof. Toni Choueiri

In this e-learning, authors prof. Brian Rini and prof. Toni Choueiri. are queried by a panel of fellow oncologists about the recent results of the Keynote-426 and Javelin 101 Renal studies.   In both phase III trials, the combination of an immunotherapy agent with the tyrosine kinase inhibitor axitinib was compared to sunitinib as first line treatment of advanced renal cell carcinoma. The panel of experts, led by prof. John Haanen, will thoroughly discuss the results of these trials with both authors.  This program provides the opportunity to gain detailed knowledge of the Keynote-426 en Javelin 101 Renal trials. Together with the authors, the expert panel will offer profound insight into the setup and execution of both trials. They will discuss the different results and assess their impact on daily clinical practice. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Motzer RJ, Penkov K, Haanen J et al. N Engl J Med 2019; 380:1103-1115. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Rini BI, Plimack ER, Stus V, et al. N Engl J Med 2019; 380:1116-1127. Authors Prof. Brian Rini, MD - medical oncologist, Vanderbilt-Ingram Cancer Center, Nashville, US; prof. Toni Choueiri, MD - medical oncologist, Dana-Farber Cancer Institute, Boston, US. Discussion panel Prof. John Haanen, MD, PhD - medical oncologist NKI-AvL, Amsterdam; Axel Bex, MD, PhD - urologic surgeon, Royal Free Hospital, London, UK; Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen.

Congress news 14/10/2019

TIMM 2019: paediatric invasive fungal infections

Chairwoman prof. Adilia Warris, MD, PhD, elaborates on the goals of the European Peadiatric Mycology Network to improve the management of invasive fungal infections. Furthermore, she shares new insights on epidemiology, diagnostic tests and treatment of invasive fungal infections in children.

Congress news 14/10/2019

TIMM 2019: mucormycosis

Anna Skiada, MD, PhD brings you up to speed on the developments on management of mucormycosis, like recent guideline updates. Also, she talks about the importance of registries for mucormycosis to get more knowledge about this potential lethal disease.

Congress news 14/10/2019

TIMM 2019: influenza-associated aspergillosis

Influenza-associated aspergillosis is a difficult problem for critically ill ICU patients. Bart Rijnders, MD, PhD, was eager to share some insights on epidemiology, etiology and management of influenza-associated aspergillosis. Moreover he elaborates on endeavors to improve outcome for these patients (e.g. research and the development of guidelines).

Congress news 01/10/2019

ESMO 2019 Highlights Breastcancer

Prof. Guy Jerusalem, MD, PhD, medical oncologist at the CHU de Liège in Belgium, shares his view on the most important ESMO news for breastcancer. 

Congress news 01/10/2019

ESMO 2019 Analysis of tumor hyperprogression with nivolumab in RCTs

Pulmonologist prof. Martin Reck from the LungenClinic Großhansdorf in Germany presented results on a relatively new phenomenon: tumor hyperprogression after treatment with immunotherapy. In the CheckMate 451 cohort, the occurence of this phenomenon with nivolumab-treated es-SCLC patients was evaluated.

Congress news 01/10/2019

ESMO 2019 Osimertinib as first-line treatment for NSCLC: final OS analysis

The FLAURA-studie compares the effectivity of the EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib to the EGFR-TKI's gefitinib of erlotinib in NSCLC. In 2018, benefit in progression-free survival was reported for osimertinib. At this ESMO congress, dr. Suresh Ramalingam (Winship Cancer Institute of Emory University), presented the results on overall survival.